Media headlines about Acceleron Pharma (NASDAQ:XLRN) have trended somewhat positive on Sunday, according to Accern. The research firm ranks the sentiment of news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Acceleron Pharma earned a news impact score of 0.17 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 45.7438906980953 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the news headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Acceleron Pharma Inc. (XLRN) Given Consensus Recommendation of “Buy” by Analysts (americanbankingnews.com)
- Acceleron Pharma Inc. (XLRN) SVP Sells $196,441.46 in Stock (americanbankingnews.com)
- Royal Bank Of Canada Begins Coverage on Acceleron Pharma Inc. (XLRN) (americanbankingnews.com)
- Acceleron Pharma Inc. (XLRN) EVP Sells $706,744.00 in Stock (americanbankingnews.com)
- Acceleron Pharma Inc. (XLRN) CFO Kevin F. Mclaughlin Sells 16,000 Shares (americanbankingnews.com)
Shares of Acceleron Pharma (NASDAQ:XLRN) traded up 0.03% on Friday, hitting $39.91. The stock had a trading volume of 528,858 shares. Acceleron Pharma has a 12-month low of $23.07 and a 12-month high of $41.69. The company has a 50 day moving average of $35.71 and a 200-day moving average of $30.87. The firm’s market capitalization is $1.54 billion.
Acceleron Pharma (NASDAQ:XLRN) last issued its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.12). Acceleron Pharma had a negative net margin of 724.22% and a negative return on equity of 44.67%. The business had revenue of $3.10 million for the quarter, compared to analysts’ expectations of $3.69 million. During the same period last year, the business earned ($0.59) earnings per share. The company’s revenue was down 3.1% on a year-over-year basis. Equities analysts predict that Acceleron Pharma will post ($2.72) EPS for the current fiscal year.
Several equities research analysts have recently weighed in on XLRN shares. Credit Suisse Group set a $35.00 price objective on Acceleron Pharma and gave the company a “buy” rating in a research note on Saturday, August 5th. Oppenheimer Holdings, Inc. reiterated a “market perform” rating on shares of Acceleron Pharma in a research note on Tuesday, June 13th. Piper Jaffray Companies upped their price objective on Acceleron Pharma from $32.00 to $40.00 and gave the company an “overweight” rating in a research note on Monday, June 26th. Cann reiterated a “hold” rating on shares of Acceleron Pharma in a research note on Tuesday, September 5th. Finally, BidaskClub lowered Acceleron Pharma from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $42.33.
COPYRIGHT VIOLATION NOTICE: This news story was posted by Transcript Daily and is owned by of Transcript Daily. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US & international trademark and copyright law. The legal version of this news story can be accessed at https://transcriptdaily.com/2017/09/17/acceleron-pharma-xlrn-receives-daily-news-sentiment-score-of-0-17.html.
In related news, CFO Kevin F. Mclaughlin sold 34,400 shares of Acceleron Pharma stock in a transaction dated Wednesday, July 5th. The shares were sold at an average price of $32.00, for a total transaction of $1,100,800.00. Following the completion of the transaction, the chief financial officer now directly owns 80,950 shares of the company’s stock, valued at approximately $2,590,400. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP John D. Quisel sold 5,113 shares of Acceleron Pharma stock in a transaction dated Wednesday, September 13th. The shares were sold at an average price of $38.42, for a total transaction of $196,441.46. Following the transaction, the senior vice president now directly owns 57,918 shares of the company’s stock, valued at $2,225,209.56. The disclosure for this sale can be found here. Over the last three months, insiders have sold 117,915 shares of company stock valued at $4,160,901. 3.90% of the stock is currently owned by corporate insiders.
Acceleron Pharma Company Profile
Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.
Receive News & Ratings for Acceleron Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.